This Report provided by 24 Market Reports is about, the colorectal cancer (CRC) market considering the sales of both branded treatments and generic chemotherapy is expected to experience a moderate growth between 2015 and 2025. The main drivers of growth will be the expected increased number of diagnosed CRC incidence and the launch and uptake of premium-priced therapies.
During the forecast period from 2012 - 2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada.
Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. See Full Report @ bit.ly/1vM6jVN
The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence.
These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).
During the forecast period from 2012-2022, the growth of the ulcerative colitis market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. See More: http://goo.gl/tW6DQL
Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. See Full Report @ bit.ly/ZrFfRz
Download Free Sample@ https://bit.ly/2V5TWKe #Market #MarketAnalysis #Chemicals #ChemicalsAndMaterial Anti Asthma Drugs Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Anti Asthma Drugs industry with a focus on the Chinese market. The report provides key statistics on the market status of the Anti Asthma Drugs manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Overall, the report provides an in-depth insight of 2014-2024 global and Chinese Anti Asthma Drugs market covering all important parameters.
TMR’s US & China Asthma and COPD Drugs Market market report helps analyze trends and significant developments in the industry. In addition, it also provides insights predicting growth rates of the US & China Asthma and COPD Drugs Market market using detailed assessment of key drivers, threats, restraints, along with opportunities that are likely to open doors for growth in coming years. For More Technical Insights, Download Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=15857
This report studies Asthma Treatment Drugs in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.
China's demand for Asthma Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow.
Marketreportsonchina.com presents a report on “Market Forecasts on China Asthma Treatment Drugs Industry 2015”. http://www.marketreportsonchina.com/life-sciences-market-research-reports-18032/asthma-treatment-drugs-industry-forecasts-china-focus.html The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed Chinas society and economy.
Big Market Research “Asthma Drugs Market in the US” Size, Share, Industry Trends, Demand, Insights, Analysis, Research, Report, Opportunities, Company Profiles, Forecast to 2019. Visit for more info @ http://www.bigmarketresearch.com/asthma-drugs-in-the-us-2015-2019-market Asthma is a disease that affects the lungs and is characterized by wheezing, coughing, breathlessness, and chest tightness. It is a chronic ailment of the respiratory tract, which is caused by the obstruction of the flow of air and bronchospasms, where the muscles around the respiratory tract swell up. The disease is believed to be caused by genetic as well as environmental factors.
Big Market Research present “PharmaPoint: Prostate Cancer - Global Drug Forecast and Market” Size, Share, Industry Trends, Demand, Analysis, Research, Report, Company Profiles, Forecast to 2023. Visit for more info @ http://www.bigmarketresearch.com/pharmapoint-prostate-cancer-global-drug-forecast-and-analysis-to-2023-market Prostate cancer is the second most common cancer in men worldwide, after skin cancer. It accounts for 15% of all the cancers diagnosed in men, and thus represents a huge burden on healthcare systems. While patients diagnosed with early-stage, localized prostate cancer can be cured, patients who are diagnosed with or progress to castration-resistant prostate cancer (CRPC) have no curative options.
GlobalData has released its new Country report, “PharmaPoint: Dry Eye Syndrome - India Drug Forecast and Market Analysis to 2022”. Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation.
The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period.
Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients’ survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems. https://www.bharatbook.com/healthcare-market-research-reports-470146/drug-healthcare-global-7.html
April 21st, 2015 – Navi Mumbai, India: Market Reports on India presents the report on "PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022" the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.
“PharmaPoint: Alzheimer’s Disease - India Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.
Download sample brochure @ http://tinyurl.com/jeu5bak This report provides comprehensive information on the therapeutic development for Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Asthma and special features on late-stage and discontinued projects.
Increasing allergic rhinitis is a major factor for allergic asthma leading to increase in research for the development of allergic immunotherapies for the treatment of asthma.
The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. See Full Report: http://goo.gl/6R29xF
Research Beam added a report on “Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023” Enquiry about report: http://www.researchbeam.com/pharmapoint-multiple-myeloma-global-drug-forecast-and-analysis-to-2023-market/enquire-about-report
GBI Research, a leading business intelligence provider, has released its latest research report, Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations. The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. Enquiry @ http://www.researchbeam.com/asthma-therapeutics-in-major-developed-to-2020-personalized-treatment-for-severe-asthma-to-drive-growth-despite-patent-expirations-market/enquire-about-report
Big Market Research present “PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis” Size, Share, Industry Trends, Demand, Analysis, Research, Report, Company Profiles, Forecast to 2023. Visit for more info @ http://www.bigmarketresearch.com/pharmapoint-melanoma-global-drug-forecast-and-analysis-to-2023-market Melanoma is the deadliest and most aggressive form of skin cancer. The major treatments for melanoma are categorized into immunotherapies and BRAF mutation-targeted therapies. GlobalData estimates the 2013 sales for melanoma at approximately $1.34 billion across the 8MM covered in this report. The market will increase by four-fold over the forecast period, reaching $5.64 billion in 2023 at a CAGR of 15.5%.
Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. More pertinently, the degree and proportion of breakthrough innovations is significant. GBI Research analysis identified 59 first-in-class programs in the asthma pipeline, acting on 43 first-in-class molecular targets, accounting for 23% of all products with a disclosed molecular target and reflective of the high degree of innovation in this indication. Enquiry @ http://www.researchbeam.com/frontier-pharma-asthma-identifying-and-commercializing-first-in-class-innovation-market/enquire-about-report
Asthma Therapeutics Market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%.
Only one older generation drug with modest efficacy had been available until the recent arrival of two new therapies that could potentially change the prescribing landscape. Will these drugs make a significant impact on the Obesity market? Which drugs are used off-label for the treatment of obesity?
Market reports on India presents the latest report on “Rheumatoid Arthritis India Drug Forecast and Market Analysis to 2023” http://www.marketreportsonindia.com/life-sciences-market-research-reports-12381/pharmapoint-rheumatoid-arthritis-india-drug-forecast-market-analysis1.html This Report analysis of the impact of key events as well the drivers and restraints affecting the India Rheumatoid arthritis market.
Increase in prevalence of target diseases including diabetes, asthma, chronic obstructive pulmonary disorder (COPD), and cardiovascular diseases coupled with rapid technological advancements in drug delivery devices are key factors driving the global electronic drug delivery systems market.
Get a detailed report at http://www.marketoptimizer.org/pharmapoint-parkinsons-disease-us-drug-forecast-and-market-analysis-to-2022.html . Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. Researcher expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.
Get a detailed report at http://www.marketoptimizer.org/pharmapoint-parkinsons-disease-japan-drug-forecast-and-market-analysis-to-2022.html . Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability.
Get a detailed report at http://www.marketoptimizer.org/pharmapoint-parkinsons-disease-5eu-drug-forecast-and-market-analysis-to-2022.html . As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.
The new PharmaPoint Drug Evaluation report, “Lonsurf (Colorectal Cancer) - Forecast and Market Analysis to 2023”. For more details : http://goo.gl/jGIpRr
The main driver of Global Drug Forecast of PharmaPoint 2025 gives the significant expansion of the ACS market will be the increase in use and physician confidence in the PCSK9 inhibitor class, which will hold four major players by the end of this forecast. See Full Report: https://goo.gl/qEFj29
RnRMarketResearch.com adds “Allergic Asthma – Pipeline Review, H1 2015” to its store. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Big Market Research : World Anti-Inflammatory Therapeutics Market - Size, Share, Trends, Demand, Report, Opportunities and Forecast 2020 To Get More Details @ http://www.bigmarketresearch.com/anti-inflammatory-therapeutic-market Inflammation is triggered by the defense system of the body in response to harmful stimuli, damaged cells, irritants and microorganisms. Inflammation is the mechanism of innate immunity, which seeks to eliminate the cause of injury, clear dead and necrotic cells and heal injured tissues. Sometimes, the body defense system inappropriately triggers inflammation against its own cells, resulting in incurable inflammatory autoimmune diseases such as arthritis, asthma and chronic obstructive pulmonary disease (COPD). According to World Health Organization (WHO), approximately 235 million people suffer from asthma in the world.
The entire market for microvascular complications of diabetes (MCD) diabetic nephropathy, retinopathy, and neuropathy is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.
Get a detailed report at http://www.marketoptimizer.org/sinemet-parkinsons-disease-forecast-and-market-analysis-to-2022.html . Sinemet (carbidopa and levodopa), developed by Merck & Co., is considered one of the gold standards for treatment in Parkinson’s disease. It is used for the control of motor symptoms in Parkinson’s disease and other Parkinsonian syndromes. Sinemet does not slow the neurodegenerative process in Parkinson’s disease, and over time patients’ responsiveness to therapy may change as they enter more advanced stages of the disease.
According to MRFR analysis, Bronchodilators Market is expected to register a CAGR of 5.30% during the forecast period of 2019 to 2025 and is expected to reach USD 2,484 Million by 2025.
Big Market Research, PharmaPoint: Global Asthma Drug Market Size, Share, Strategies, Trends, Application, Forecast, Demand, Analysis, Research, Report, Opportunities. Big Market Research added a new research report "PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023". Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade. The largest unmet needs mainly reflect the high level of heterogeneity of the disease, the lack of patient compliance with the standard therapies, and the high cost of medications for asthma treatment. In addition, there is a lack of diagnostic tools to provide a reliable diagnosis of asthma in young children. Annualized asthma therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
Finding of asthma exacerbations with 24 mcg BID dose warranted additional ... by Novartis that can improve the understanding of the nature and magnitude of ...
Big Market Research, Global Pharma Point Macular Edema and Macular Degeneration Drug Market Size, Share, Trends, Application, Forecast, Demand, Analysis, Research, Report, Opportunities, Segmentation to 2023. Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). The ME market has been dominated by anti-VEGF drugs Lucentis and Avastin for many years, however, rival drug Eylea has recently gained approval for ME indications across the 7MM. How will this impact the positions that Lucentis and Avastin hold in this market.
Big Market Research, Global Pharma Point Colorectal Cancer Drug Market Size, Share, Trends, Application, Forecast, Demand, Analysis, Research, Report, Opportunities, Segmentation to 2023. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. By 2023, the end of the forecast period, GlobalData projects CRC sales to rise to $8.11 billion in the 8MM, at a moderate Compound Annual Growth Rate (CAGR) of 4.9%. Major drivers of the growth of the CRC market over the forecast period include increasing CRC incident cases, the launch of premium-priced adjuvant and maintenance treatments for first-line metastatic disease, and the launch of pipeline agents for later-line CRC. Annualized Colorectal cancer therapeutics market revenue, annual cost of therapy, and treatment usage patterns in eight patient segments, forecast from 2013 to 2023.
Global Preventive Asthma Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape of the global preventive asthma drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Big Market Research, Global PharmaPoint HER2-Positive Breast Cancer Drug Market Size, Share, Trends, Application, Forecast, Demand, Analysis, Research, Report, Opportunities, Segmentation, to 2023. HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic. This report forecasts that the two monoclonal antibodies that also target the HER2 receptor will ensure Roche still occupies over 95% of the market in 2023. The challenge for new entrants into the HER2-positive market is to find patient populations that are currently underserved, and can work cooperatively with Roche’s targeted therapies.
Global COPD and asthma devices market to grow at a CAGR of 3.76% over the period 2014-2019. COPD and asthma devices are used for inhalation therapy. These devices convert drug suspensions or solutions into aerosolized particles, assisting in drug delivery in individuals with breathing problems.
The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden. Complete report is available @ http://www.rnrmarketresearch.com/pharmapoint-hemophilia-a-and-b-argentina-drug-forecast-and-market-analysis-to-2022-market-report.html .
China's demand for Asthma Treatment Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Detailed report at: http://www.reportsandintelligence.com/asthma-treatment-drugs-in-china-market
“Sutent (Renal Cell Carcinoma) - Analysis and Forecasts to 2022” provides Sutent sales forecasts for US, EU5 and Japan. Browse full report @ http://bit.ly/1F4Ud1X
Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. See Full Report @ bit.ly/12yBegp